Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 Next >
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces First Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Appoints Annie McGuire as General Counsel
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Third Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.